Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...
Walmart and Target Recall Frozen Waffles Due to Listeria—Check Your Kitchen Now
Many frozen waffle brands distributed by TreeHouse Foods have been recalled due to listeria contamination at various major ...
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
F.D.A. Names a New Chief of Medical Devices
Patient advocates hope Dr. Michelle Tarver will lead the agency to focus more on safety and less on rapid approvals.
FDA Has Recalled Thousands of Bottles of Antidepressant Duloxetine, Sold Under Brand Name Cymbalta: Here’s Why
The Duloxetine Delayed-Release Capsules' voluntary recall began on Oct. 10 after the FDA deemed the medication the ...
FiercePharma22m
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
BioSpace1h
Novo Makes Case to FDA That Semaglutide Is Too Complex for Compounders to Produce
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Hosted on MSN46m
FDA Recalls Thousands of Bottles of Antidepressant Duloxetine: Here's Why
In a shocking turn of events, over 7,100 bottles of the antidepressant Duloxetine were recalled due to a potential cancer ...
FDA approval for Cobenfy casts light on schizophrenia’s wickedness
FDA-approved Cobenfy offers a novel treatment for schizophrenia, targeting cholinergic receptors instead of dopamine, with ...
STAT15h
Novo asks FDA to bar compounders from making Ozempic copies
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...